Vinczeller Shiela sold $400K of ATR

Vinczeller Shiela (Chief Human Resources Officer) sold 3,555 shares of APTARGROUP, INC. (ATR) at an average of $112.61 ($112.36–$114.53, $0.40M total) across 3 trades on 2026-06-04.

Original reporting
SEC EDGAR · Vinczeller Shiela
Published Jun 5, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATR
Neutral
medium confidence
Mentioned
$ATR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRNeutralLow
01

Why it matters

The sale is a primary disclosure; while the amount is modest, it signals potential insider sentiment.

02

Market read

A small insider sell that may cause slight short-term pressure on ATR.

03

Timing

post-market June 5

Relevance 4/10Novelty 4/10Timing: post-market June 5

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$ATRNeutralMedium confidence
Context

Chief Human Resources Officer sold $400K of shares, reducing her stake to 27,078 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A $400K sale by a C-suite executive is material enough to be noted but the amount is modest relative to market cap.

Key entities

  • Vinczeller Shiela

    Chief Human Resources Officer of Aptargroup, Inc.

  • Aptargroup, Inc.

    Issuer of the shares sold.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATRHighAI 8/10

Aptar Q3 2026 slides: broad growth, strong Pharma pipeline

AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.

$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

$ATRMedAI 8/10

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.